Engineering better cytokines
- 1 November 2003
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 21 (11), 1293-1294
- https://doi.org/10.1038/nbt1103-1293
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Targeting cytokines to inflammation sitesNature Biotechnology, 2003
- TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseasesNature Medicine, 2003
- α4Integrins as Therapeutic Targets in Autoimmune DiseaseNew England Journal of Medicine, 2003
- Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamineNature Medicine, 2002
- Combination of Gene Delivery and DNA Vaccination to Protect from and Reverse Th1 Autoimmune Disease via Deviation to the Th2 PathwayImmunity, 2001
- Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: A pivotal role for stromelysin 1 in matrix metalloproteinase activityArthritis & Rheumatism, 1999
- ImmunocytokinesPharmacology & Therapeutics, 1998
- Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.JCI Insight, 1994
- Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple SclerosisArchives of Neurology, 1987